Credits Available: 5.0 AMA PRA Category 1 Credits

Description: The proposed activities will inform clinicians of recent evidence from clinical trials on the efficacy and safety of TROP2-directed antibody-drug conjugates (ADCs) in patients with progressive NSCLC, allowing them to quickly integrate new treatments into their practice when they become available. Clinicians will be updated on HER2 genomic alterations and apply appropriate testing methodologies per the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC. Furthermore, participants will receive education on the successful management of NSCLC, including managing brain metastases, optimal HER2-targeted ADC dosing, and monitoring approaches for treatment-related adverse events (AEs). Finally, the proposed activities aim to educate participants on the importance of targeting HER3 and using HER3-directed ADCs in the management of NSCLC. The initiative will also provide information on the efficacy and safety of these ADCs based on clinical trial data, as well as strategies for recognizing and minimizing treatment-related AEs to enhance therapy adherence and improve patient outcomes.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology

Jasmine Patel

Memorial Sloan Ketting Cancer Center

I am a clinical oncology pharmacy specialist in Thoracic Oncology at Memorial Sloan Kettering Cancer Center. I previously trained and worked at Boston Medical Center where my focus was primarily ambulatory oral targeted therapy/chemotherapy. I have done previous grant work with metastatic breast cancer, prostate cancer and disparities in care, and targeted therapy with non-small cell lung cancer. My areas of interest include education, targeted therapies, and disparities in cancer care.